Contract

Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3

Agency: DEPT OF DEFENSE / DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)
Location: ARLINGTON, VA
Amount: Amount not listed
Deadline: Closes in 11 days (Jul 29, 2026)
Posted: Jul 2, 2026
Set-aside: None (open competition)
NAICS code: 541714

What this contract is for

Please note that this announcement specifically solicits proposals only for Task Area 3 (TA-3) of the RAPIID program. Primary challenges with translating technological advancements from the laboratory to real-world usage include a lack of investment to ensure manufacturing scalability, and usability, as well as clinical, regulatory, and commercialization preparedness. Previous investments by DARPA to address potential blood shortages in austere, pre-hospital settings (i.e., the Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP) program) have derisked scalable, shelf-stable components that would provide the resuscitative functions of whole blood (i.e., oxygen delivery, hemostasis, and volume expansion) when used together. However, bringing those components through clinical studies and regulatory approval as well as the development of enabling technologies and guidance to facilitate their use outside of the laboratory were out-of-scope in previous DARPA efforts. RAPIID is designed to bridge the gap between the proof-of-concept achievements of the FSHARP program and actual clinical use by the military and civilians. With FSHARP demonstrating that shelf-stable blood products can be created, DARPA is now taking on the next challenge: delivering a complete, deployable, and authorized system that can save lives in the field. To achieve this goal, RAPIID will focus on pushing high technology readiness level (TRL)/medical readiness level (MRL) capabilities through the regulatory process by funding studies to demonstrate safety and efficacy of blood analog components and their ability to work in combination; manufacturing scalability of individual blood analog components; and developing and scaling associated fielding technologies.

View the official listing on SAM.gov

Oppward is an independent service and is not affiliated with, endorsed by, or sponsored by SAM.gov or any government agency. This page is a plain-English summary of public record data; the linked source above is the authoritative listing.

How to bid on this

This is a contract solicitation, not a grant. To bid, you submit a proposal (usually a price and a description of how you would do the work) directly to the government, through the channel the official listing specifies, not through Oppward.

Make sure your business has an active SAM.gov registration. You cannot be paid on a federal contract without one.
Read the full solicitation on the official listing above, especially the scope of work, not just this summary. Our guide to reading a solicitation walks through what to look for.
This listing has no set-aside restriction ("full and open competition"), meaning any business, large or small, can bid.
Submit your proposal by the deadline, using the exact submission method the official listing states. A technically on-time bid sent the wrong way is often treated as late.